Abstract Recent publications primarily relate to advances in central precocious puberty (CPP), with little new information concerning the diagnosis and treatment of peripheral precocious puberty (PPP). New information concerning CPP is centered on newer treatment options, all of which involve newer modes of delivering GonadotropinReleasing Hormone analog therapy. Recent publications about CPP and the association with CNS lesions, malnutrition and catch-up growth and more efficient ways to predict and document pubertal luteinizing hormone secretion will be discussed. In this article, we will review these newer developments as well as psychological issues, sexual behavior, bone mineral density and body mass index in relation to CPP and its treatment, as well as long-term outcome information on adults previously treated for CPP. Over time, additional observations have allowed a refinement of the diagnostic process, the definition of characteristics during therapy, and more verification of outcome and safety parameters. In summary, a combination of findings should be used to help document the diagnosis of CPP, and therapy should be considered when progression may cause untimely development and limited growth, while the dosing used and the best tools for monitoring therapy effectiveness remain unclear.
Introduction
The diagnosis of central precocious puberty (CPP) has been improved significantly with the development of more sensitive gonadotropin and sex steroid assays. The diagnosis of CPP involves both biochemical documentation but also involves demonstration of an early onset of sexual characteristics, the progression of these physical pubertal changes and an accelerated linear growth. Treatment strategies all involve the use of continuous Gonadotropin-Releasing Hormone analogue (GnRHa) delivery to downregulate a pubertal pituitary. GnRHa therapy, when used in a longacting form, has been shown to be effective at arresting/ slowing pubertal progression with the goal of discontinuing therapy, and the pubertal suppression stemming from it, until an age where pubertal progression is desired.
This review cites recent publications and also discusses newer information regarding pathologic causes of CPP, the appropriate use of screening magnetic resonance imaging (MRI), and the phenomenon of fetal/neonatal undernutrition and the importance of catch-up growth during prepubertal years for an optimal outcome. Observations during GnRHa therapy for treatment of CPP include discussion of long-acting preparations (3-month leuprolide acetate and triptorelin), monitoring for hormonal suppression during treatment, growth rates while on treatment and the changes in BMD and BMI that can be seen during GnRHa therapy. Outcome discussions include reproductive information and adult heights.
Recent Overview
Newer information regarding precocious puberty involves improved and simplified hormonal diagnostic techniques, and further outcome information indicating safety and efficacy. Precocious puberty is defined based on age of onset of physical changes, although the precise cut-off ages are not well-defined and vary based on racial/ethnic groups. The overall approach involves the two categories of CPP and PPP, after variations of normal development including premature thelarche and pubarche are eliminated. Progression of the physical changes, accelerated growth rates and skeletal age advance are characteristic of precocious puberty, with CPP diagnosed by evidence of pituitary gonadotropin secretion (a pubertal hypothalamic-pituitarygonadal axis) while PPP is a consequence of sex steroid stimulation of physical changes as a consequence of endogenous or exogenous steroid or gonadotropins from pathologic sources. GnRHa therapy is the treatment of choice for CPP, while therapy for PPP is specifically or generally used to treat the underlying cause.
While this article does not allow space to fully review precocious puberty, a recent review article details an overview of precocious puberty [1] . Goals of therapy are defined as halting or causing regression of secondary sexual characteristics, prevention of early menarche, retardation of skeletal maturation and improvement of adult height and avoidance of psychological/behavioral sequelae.
Age of Normal Pubertal Onset
An ongoing issue in the diagnosis of precocious puberty remains the definition of the normal age of pubertal onsetwhich has been poorly documented in North America in the past-and the differences in pubertal onset between racial/ ethnic groups. A recent report on boys between 2005 and 2010 found that the mean age of genital, pubic hair and testicular growth had declined by 6 months to 2 years [2 •• ]. This report documents an earlier mean age for stage 2 to 4 genital and pubic hair staging in African-American boys than in their White or Hispanic counterparts. The mean age for reaching certain pubertal milestones have been listed in Table 1a . These data, which are similar to that previously reported for girls, show that there are distinct ethnic differences in pubertal onset in both sexes, and underscores the ongoing difficulty with establishing a clear age cutoff for early puberty in multi-ethnic societies, making even defining precocious puberty an inexact endeavor.
More importantly, it is not clear which physical pubertal findings at the initial evaluation (save for testicular volume) best correlate with a pubertal hypothalamic-pituitarygonadal (HPG) axis. With maturation of this axis, there is greater release of gonadotropins, particularly LH. This can be verified as discussed below, by a basal LH level above the pubertal range for the assay used, or by a pubertal response of GnRH or GnRHa stimulation testing. FSH levels or ratios of LH:FSH add limited information concerning this axis. CPP is progressive, so within a few months breast development and other findings will advance, together with an accelerated growth rate, and given enough time, the rate of skeletal maturity will advance. For CPP, such changes will be accompanied by evidence of a pubertal HPG axis, which can be verified by biochemical testing. If the clinical picture is unclear, time permits a more thoughtful approach through the documentation of pubertal progression on serial examinations. It is important to recognize that puberty is a multidimensional process and does not rest solely on the identification of a single sexual/pubertal change (such as isolated pubic hair or breast development). For example, girls with early breast development and but little progression over the course of a year may not have true progressive puberty. In boys it can be assumed that the increase in testicular volume is a result of gonadotropin secretion, particularly FSH, but it is unclear at what point this is indicative of the onset of progressive puberty.
Further, because of the paucity of data regarding the earliest changes of puberty, especially in relation to racial/ ethnic differences, it is difficult to make conclusions about the onset of puberty as well as any change in trends over time. While progressive puberty will be manifest in a child with CPP, the medical profession needs more information to judge changes in the normal age range of onset of puberty, since historically data are limited and based primarily on White children, rather than other racial/ethnic groups. The authors of this recent report for boys have recognized this problem and appropriately refer to the ''apparent shift in American boys to a lower age of onset of the development of secondary sexual characteristics'', rather than stating that an earlier onset of puberty has been identified in American boys. Such data make it necessary for the clinician to carefully assess each patient presenting with early puberty, determining not only whether puberty is occurring, but also if a pubertal HPG axis is present, whether such a presentation is truly early for this patient and if therapy should be considered.
A longitudinal study of children (Table 1b) with normal onset of puberty explored the association between gonadarche (thelarche for girls and TV increase in boys), adrenarche (onset of pubertal levels of adrenal androgen secretion), pubarche (onset of sexual hair, particularly pubic hair development) and body composition found no association between pubertal onset and body composition (based on BMI and skin fold thickness) among children from higher socioeconomic backgrounds [3 • ]. This report also verified that the appearance of pubic hair is rarely the first sign of puberty; found in only 6.8 % (4/59) of girls and in 24.6 % (15/61) of boys, pubic hair growth may be a consequence of either/or both adrenal and testicular androgen.
Etiology

CNS Lesions
It has long been clear that some patients have CPP as the consequence of a central nervous system (CNS) neoplasm that may act directly or indirectly upon GnRH secretion. An extensive review article has summarized CNS tumors and other CNS lesions including those induced by radiation therapy, trauma, infection or bleeding and their relationship to CPP [4] . Table 2 categorizes the etiologic factors for lesions associated with CPP. The specific mechanisms resulting in early GnRH secretion are unknown. Because CPP has been noted with hydrocephalus alone, the associations between CPP and CNS lesions may be secondary to increased intracranial pressure.
When categorizing CNS tumors associated with CPP, the usual classification for CPP indicates physiologically normal (albeit beginning at an early age) pubertal HPG function. Hence, CPP may also be referred as GnRHdependent precocious puberty. Such a classification excludes gonadotropin-dependent precocious puberty as a consequence of gonadotropin secreted by differentiated tumors, such as hCG secreting tumors. Such tumors may represent a germ cell tumor that can occur within the CNS (or gonad, liver,and mediastinum) or as well as hepatoblastomas. This publication [4] groups all these categories as gonadotropin-dependent precocious puberty, rather than GnRH-dependent. The latter is more consistent with the category of CPP, since it involves hypothalamic, or accessory hypothalamic tissue in the instance of the hamartoma, all of which can be treated with GnRHa. GnRHa therapy would not be effective for the very rare gonadtropin-producing tumors, and as such are better classified as a peripheral form of precocious puberty. The difference in the categories is that for CPP puberty results from HPG activity, while PPP can result from all other sources.
Magnetic Resonance Imaging (MRI)
One frequent point of controversy revolves around when MRI should be employed in children with CPP, particularly in girls, in whom CPP is more common and in whom CNS lesions occur much less frequently. In a recent study of girls with both early and precocious puberty, 54 had abnormal MRI findings, 21 had known CNS conditions, and 20 had incidental findings; 13 of 208 (6.3 %) the girls with precocious puberty, all of whom had no other signs of CNS symptoms, also had brain pathology identified by MRI [5] . These 13 girls were all 6 to 8 years old. The lesions included arachnoid cysts in five patients, while other lesions were hypothalamic hamartoma, pilocystic astrocytoma, hydrocephalus and corpus callosum agenesis, hamartomas (basal ganglia, brainstem, cerebellum) and neurofibromatosis type 1, pineal tumor, Chiari II malformation, left occipital lobe cortical dysplasia and pontine tumor. Among the 13, no clinical or biochemical parameters were predictive of a pathologic finding on brain MRI.
The authors suggest that all girls with CPP and early but rapidly progressing puberty should be evaluated by a brain MRI, regardless of age. However, it is unclear if the population of this study is characteristic of children diagnosed with CPP overall. Since CNS lesions are rarely demonstrated by MRI among girls older than 6 years and most of such lesions require no therapy, it still is unclear if MRI should be mandated among all such patients, while such studies should be done among girls with unusually rapidly progressing puberty or vague developmental or physical neurologic signs or symptoms, with the onset was precocious or within the early range.
Catch-up Growth
The phenomenon of an increased frequency of CPP among those removed from a deprived environment and placed into a better, more supportive environment with good nutrition has been observed for some time. This is being seen more frequently with the increase in international adoptions. Also, it has long been considered that precocious puberty may occur earlier among those with intrauterine growth retardation. Underlying mechanisms are unknown, as are influences originating in fetal life or from postnatal growth. A recent review [6] focuses on fetal, postnatal and fetal-postnatal undernutrition and subsequent catch-up growth including catch-up growth in relation to pubertal development. While catch-up growth in children can be associated with early puberty following fetal or combined fetal-postnatal undernutrition, early puberty does not seem to occur following catch-up growth after isolated postnatal undernutrition. Gonadotropins have been reported to be elevated in prepubertal adopted girls. While there appears to be an association between catch-up growth and timing of pubertal development, the mechanisms that underlie this association remain unknown.
Diagnosis
Documentation of Pubertal LH Secretion
The most efficient way to verify a pubertal HPG axis for the diagnosis of CPP remains unclear. Random LH levels within the pubertal range and above the pre-pubertal range using ultrasensitive assays remain an effective screening tool and may avoid the need for stimulation testing. Alternatively, in those children needing it, GnRHa stimulation can be efficient, definitive and brief. While it has been reported that a single sample after GnRHa stimulation test at 1 hour is sufficient to identify CPP in 88 % gonadotropin measurement at 3 h post stimulation were 100 % predictive [7] , we would agree that a 30 min sample is as good as later samples for those with CPP, even though the response among those without CPP continued to rise after this time [8 • ]. This report, plus another recent report finding that either a 20 or 40 min sample was reported to be sufficient [9] , adds to the growing credibility of this more efficient diagnostic approach.
Factors Predicting GnRH Positive Testing
In an effort to identify factors among girls presenting with possible CPP that predict a positive pubertal response to GnRH testing, were analyzed the characteristics of 574 girls, 375 of whom had CPP [10] . The most significant predictive factors were growth acceleration, advanced bone age and higher basal levels of LH, FSH and estradiol. These factors should be used as important clinical milestones to determine which child should be assessed and treated for CPP.
Psychological Factors
Significant psychological problems have not been documented among those with CPP. An evaluation of behavioral patterns and social competencies in 34 girls with CPP and control girls with a normally timed puberty found precocious girls had higher T scores in total social competence, school scales and behavioral problems, as well as for behavioral, thought and attention problems [11] . However, these scores were still considered to be in the normal behavioral range and were not considered clinically important.
Psychological Problems and Sexual Behavior
The recent overview of precocious puberty indicates that psychological problems may arise as a result of pubertal levels of sex steroids, resulting in adolescent behavior [1] . Further, older references are cited that such problems may arise from altered self-image or from expectations of behavior more consistent with the advanced physical maturity rather than actual age, and that girls are at increased risk for sexual abuse and early pregnancy. None of these primarily theoretical problems have been verified and such statements should be carefully qualified if cited as significant issues. Although the study did not focus on girls with precocious puberty, one twin study may provide some guidance on this question. Despite scant historical evidence of a higher risk of sexual behavior problems or victimization in CPP for girls and the lack of any newer studies demonstrating this, many clinicians continue to feel a risk exists. Even among normal children, there continues to be minimal evidence to substantiate a relationship between the age of pubertal development and the risk of sexual victimization, early initiation of sexual behaviors or development of high risk sexual behaviors, including multiple partners of both sexes without protection. Nevertheless, it has been assumed that there is an association between the age of sexual initiation and subsequent risky adult sexual behavior. The presence of a causal relationship was explored, not specifically in CPP, but in a longitudinal sample of 2,173 twins [12] . One group, aged 11-24 years, controlled for unmeasured genetic and shared environmental factors and a second group, aged 17-29 years, controlled for measured, non-shared environmental factors. A link between sexual initiation and risky behaviors was found, but this association appeared to be explained by common genetic and/or environmental risk factors. These authors suggest that delay of age of initiation is unlikely to reduce risky behaviors. This may apply to the child with CPP, who has been thought to have earlier initiation of behavior related to earlier maturity.
GnRHa Therapy
Monitoring LH Suppression During Therapy
The prospective US multicenter trial of leuprolide acetate 1-month depot, using 7.5, 11.25 and 15 mg doses involved treatment for 3.9 ? 2.0 years [13 • ], was recently published. Suppression was assessed using LH response to GnRH stimulation testing. Peak LH and FSH mean levels were prepubertal (\1.75 IU/L for LH and \2.5 IU/L for FSH) 30 days after the first dosage and remained suppressed throughout treatment. Estradiol among girls was suppressed below the limits of the assay (20 pg/mL) while for boys testosterone remained above the prepubertal range, but within the range of a pubertal aged boy with adrenarche only (\30 ng/dL).
LH Random and Stimulated Peak of LH During Implant Therapy
It continues to be unclear what level of hormonal suppression is associated with the best clinical outcomes, as well as whether basal levels of LH during therapy are sufficient to document suppression while on treatment, or whether GnRH stimulation testing is necessary. The following study suggests that basal levels are not adequate, although if suppression is present with stimulation while basal levels are not, the reason for higher basal levels is unexplained. One possible explanation for a pubertal LH level despite good clinical suppression in children treated for CPP proposes that the LH molecule being measured has been altered so it is biologically inactive.
The use of random ultrasensitive (US) luteinizing hormone (LH) levels to monitor children being treated with a histrelin implant for CPP has been evaluated [14] . Using data from 33 children (26 girls) treated for CPP, random ultrasensitive LH measurements obtained at 6 months were compared to peak ultrasensitive LH levels after GnRHa stimulation testing at 12 months. Seventeen of 29 (59 %) children had 6-month random LH levels that exceeded the prepubertal range of B0.3 IU/L and while basal LH levels at 6 months were highly correlated with peak-stimulated LH levels at 12 months, all 31 children tested had peak LH \4 IU/L. The mean peak-stimulated LH level was higher in patients with a pubertal random LH than in those with a prepubertal random LH (1.2 ± 0.5 IU/L vs 0.5 ± 0.1 IU/L; P \ .01). No patient had clinical evidence of pubertal progression. These limited data suggest that the immunologic LH level does not always revert to a prepubertal range in patients with a histrelin implant who nonetheless show adequate HPG axis suppression. This study, suggesting that random LH levels may not be sufficient to verify suppression during GnRHa therapy, needs to be verified. Overall, it is still unclear whether suppression is best defined by basal (random) or GnRHa stimulated LH levels or more importantly what surrogate of adequate suppression should be used for monitoring treatment.
Growth Rates During Therapy with Leuprolide
One-Month Depot Therapy Figure 1 plots growth rates during treatment with the once monthly depot leuprolide acetate in a prospective multicenter clinical trial [15] . Growth rates decreased from a mean of 10.5 cm/yr prior to therapy to a range from 3.4 to 5.6 cm/yr during the first 5 years of the study. While many children grew within the target range of 5 to 6 cm/yr, some grew at a slower rate-particularly those treated for more than 3 years. Diminished growth rate may be related to advanced bone age present among some of the study subjects, while the impact of degree of hormonal suppression (gonadotropin or sex steroid levels) or the relationship between insulin-like growth factor 1 (IGF1) upon growth rates is unknown. The adult heights of the female from this protocol are noted in the outcome section below.
Bone Mineral Density (BMD)
Overall, BMD has not been a concern among those with CPP treated with GnRHa, particularly considering that therapy is discontinued before the adolescent years, when most bone accrual occurs. Further documentation of normal BMD has been reported for 12 girls with CPP who showed a slightly increased lumbar spine BMD for age, which normalized following correction for bone age, compared with 14 control girls [16] . BMD after 3 years of therapy failed to demonstrate a difference between the treated and the control group.
Body Mass Index (BMI) During Therapy
There has been much ongoing discussion about the impact of GnRHa therapy upon BMI, without any documentation of whether or not there is a persistent effect on BMI after treatment discontinuation. A 2012 report found that BMI SDS was significantly increased during GnRHa treatment among 38 CPP girls treated for more than 18 months with the BMI increasing more in normal weight than in overweight girls [17] . The safety and efficacy of the 3-month deport leuprolide acetate formulation has been reported for the treatment of CPP, using 11.25-and 30-mg doses from a phase III, randomized, open-label 6-month study. Eighty-four children diagnosed with CPP (with both treatment naïve or previously GnRHa treated patients) were studied. Inclusion criteria included: pubertal onset \8 yr in girls and \9 yr in boys and skeletal age advanced over chronological age at least 1 yr. Outcome measures included peak LH after GnRHa stimulation, estradiol in girls and testosterone in boys, growth rate, bone age acceleration, physical pubertal changes and safety assessment. Suppression as defined by peak-stimulated LH \4 IU/L was noted 2 months after the first injection in 78.4 % of the 11.25-mg dose group and in 95.2 % of the 30-mg group. Using this end-point, there were nine treatment failures (peak-stimulated LH[4 IU/L) in the 11.25-mg group (33.2 %) and two in the 30-mg group (4.8 %), while basal sex steroid suppression, growth rates, physical pubertal change, bone age advancement, and adverse events were similar with both doses. Not surprisingly, previously treated patients remained well suppressed throughout the study, while treatment naïve patients on the lower dosage took longer to suppress. However, these data do not address the issue of whether long-term outcome differs, based on such an index of suppression. Percentages with adverse events and other side effects were similar for both dosages.
This study again raises questions regarding what criteria should be used to document sufficient suppression plus rationale for assigning dosing. The indication for the use of these preparations further challenges the basis for dosing since no weight-based dosing criteria are used. While it is reasonable to have multiple criteria to judge suppression, those that relate to pubertal progression and growth require Fig. 1 Mean ± SE annualized growth rates for females treated with GnRHa calculated at 24 week intervals months of observation. Further, it is unclear which cut-offs to use as criteria for adequate suppression when monitoring hormone levels. During this short study, it is unclear whether the long-term outcome will show any differences between treatment doses used.
Triptorelin 11.25 mg 90-Days-3-Month
Treatment of CPP with triptorelin 11.25 mg given at 90 day (3-month) intervals has been reported to be efficacious in 17 patients (16 females) with CPP after 3, 6 and 12 months of therapy [19] . At all times, peak LH after GnRH stimulation was \0.3 IU/L. Levels at 3-months were 0.9 ? 0.5 IU/L and they did not change at 6 and 12 months, documenting suppression after the first dosage interval with persistence for 1 year. Note that the 3-month dosage interval is 90 days, more closely approximating a year after four injections as compared to 12-week intervals.
Post-Therapy Outcome
Growth and Reproductive Function After Depot Leuprolide Acetate One-Month Preparation
The long-term outcome of the one-month depot leuprolide acetate prospective multicenter clinical trial using the 7.5, 11.25 and 15 mg dosing for 3.5 ? 2.2 years has been reported. Post-treatment follow-up regarding hormonal secretion, growth and reproductive factors involved clinical visits and questionnaires until 26 years of age. The response to GnRH stimulation testing among most patients was pubertal post-therapy by 6 months or before, and within a year for all [13 • ]. Among females, menses began or recurred (in those who had menarche before therapy) among twothirds within 2 years of discontinuing therapy, and among all within 3.5 years. Subsequently, 80 % reported regular menses and none have reported fertility problems; 7 of 12 who completed the questionnaire between 18 and 26 years of age reported one or more successful pregnancies with normal children. Mean growth rates for several years after discontinuation of therapy are shown on the right hand portion of Fig. 1 . Note that there is only minimum evidence of a growth peak after therapy. Average adult height [15] , available for 30 of the 49 females in this study was 162.5 cm, -0.1 SD of normal adult female heights in the United States. Mean target height was 163.8 cm (n = 29) and mean pretreatment predicted adult height was 157.4 cm (n = 27). Mean height gain over predicted height was 4.0 cm. It should be kept in mind that delay of treatment or no treatment would be expected to result in progressive reduction of predicted and actual adult height. Hence, therapy precludes further reductions in adult height.
Conclusion
Current information suggests that the treatment of CPP with GnRHa is efficacious and safe. Careful criteria to make the diagnosis are key to be sure that there is not an underlying CNS lesion that needs additional therapy. Diagnosis can often be simplified using ultrasensitive assays to verify pubertal LH secretion. The primary reason for therapy continues to be to allow the child to develop in an age appropriate manner, while adult height is preserved or reclaimed. BMD is not a concern, while impact upon BMI and factors impacting growth rates during therapy need to be further documented. Newer treatment preparations, the newest being 3-month depot injections, simplify the therapy and likely enhance compliance. Available outcome data suggest that both general and reproductive health after therapy is similar to the general population, and adult heights are within the normal range.
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